[
    {
        "content": "* Q3 earnings per share view $-0.49 -- Thomson Reuters I/B/E/S",
        "date": "11012017",
        "name": "Neurocrine Biosciences Inc",
        "news_type": "topStory",
        "symbol": "NBIX",
        "title": "BRIEF-Neurocrine Biosciences reports Q3 loss per share $0.13 "
    },
    {
        "content": "* Neurocrine initiates phase IIb clinical study of once-daily Ingrezza in children and adolescents with Tourette syndrome",
        "date": "10252017",
        "name": "Neurocrine Biosciences Inc",
        "news_type": "topStory",
        "symbol": "NBIX",
        "title": "BRIEF-Neurocrine initiates Phase IIb clinical study of Ingrezza "
    },
    {
        "content": "* Neurocrine granted FDA orphan drug designation for valbenazine for the treatment of pediatric patients with Tourette syndrome Source text for Eikon: Further company coverage:",
        "date": "10232017",
        "name": "Neurocrine Biosciences Inc",
        "news_type": "topStory",
        "symbol": "NBIX",
        "title": "BRIEF-Neurocrine granted FDA orphan drug designation for Valbenazine "
    },
    {
        "content": "* Neurocrine announces FDA approval of 80 mg Ingrezza\u00ae (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD)",
        "date": "10052017",
        "name": "Neurocrine Biosciences Inc",
        "news_type": "topStory",
        "symbol": "NBIX",
        "title": "BRIEF-Neurocrine announces FDA approval of 80 mg Ingrezza "
    },
    {
        "content": "* Perceptive Advisors LLC reports 5.3 percent passive stake in Neurocrine Biosciences Inc as of September 6  2017 - SEC filing\u200d\u200b Source: (http://bit.ly/2wOUVQY) Further company coverage:",
        "date": "09082017",
        "name": "Neurocrine Biosciences Inc",
        "news_type": "topStory",
        "symbol": "NBIX",
        "title": "BRIEF-Perceptive Advisors reports 5.3 pct passive stake in Neurocrine Biosciences "
    },
    {
        "content": "* Q2 earnings per share view $-0.66 -- Thomson Reuters I/B/E/S",
        "date": "08032017",
        "name": "Neurocrine Biosciences Inc",
        "news_type": "topStory",
        "symbol": "NBIX",
        "title": "BRIEF-Neurocrine Biosciences Q2 loss per share $0.68 "
    },
    {
        "content": "* Neurocrine Biosciences Inc - has been advised that PDUFA goal date is october 14  2017 for Ingrezza 80 mg capsules - sec filing Source text for Eikon: (http://bit.ly/2spiVra) Further company coverage:",
        "date": "07052017",
        "name": "Neurocrine Biosciences Inc",
        "news_type": "topStory",
        "symbol": "NBIX",
        "title": "BRIEF-Neurocrine Biosciences says PDUFA goal date is Oct. 14 for Ingrezza 80 mg capsules "
    },
    {
        "content": "* Neurocrine announces phase ii results of vmat2 inhibitor ingrezza\u00ae for treatment of tourette syndrome",
        "date": "05232017",
        "name": "Neurocrine Biosciences Inc",
        "news_type": "topStory",
        "symbol": "NBIX",
        "title": "BRIEF-Neurocrine Bio's Ingrezza fails study in pedriatric Tourette's patients "
    },
    {
        "content": "* Q1 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S",
        "date": "05092017",
        "name": "Neurocrine Biosciences Inc",
        "news_type": "topStory",
        "symbol": "NBIX",
        "title": "BRIEF-Neurocrine Biosciences reports Q1 loss per share $0.90 "
    },
    {
        "content": "* Priced offering of $450.0 million aggregate principal amount of 2.25% convertible senior notes due 2024 Source text for Eikon: Further company coverage:",
        "date": "04262017",
        "name": "Neurocrine Biosciences Inc",
        "news_type": "topStory",
        "symbol": "NBIX",
        "title": "BRIEF-Neurocrine Biosciences prices $450 mln convertible senior notes offering "
    },
    {
        "content": "The U.S. Food and Drug Administration approved Neurocrine Biosciences Inc's drug to treat tardive dyskinesia  a side effect of antipsychotic medications characterized by uncontrolled movements of the face and body  the company said.",
        "date": "04122017",
        "name": "Neurocrine Biosciences Inc",
        "news_type": "topStory",
        "symbol": "NBIX",
        "title": "Neurocrine Biosciences gets FDA's OK for movement disorder drug "
    },
    {
        "content": "April 11 The U.S. Food and Drug Administration approved Neurocrine Biosciences Inc's drug to treat tardive dyskinesia  a side effect of antipsychotic medications characterized by uncontrolled movements of the face and body  the company said.",
        "date": "04122017",
        "name": "Neurocrine Biosciences Inc",
        "news_type": "normal",
        "symbol": "NBIX",
        "title": "UPDATE 1-Neurocrine Biosciences gets FDA's OK for movement disorder drug "
    },
    {
        "content": "April 11 The U.S. Food and Drug Administration on Tuesday approved Neurocrine Biosciences Inc's drug to treat tardive dyskinesia  a side effect of antipsychotic medications characterized by uncontrolled movement of the face and body  the company said. The drug  Ingrezza  is the first treatment to be approved for the irreversible disorder  which occurs in 5 percent to 8 percent of patients taking antipsychotic drugs. Ingrezza is the company's first commercial product.",
        "date": "04112017",
        "name": "Neurocrine Biosciences Inc",
        "news_type": "topStory",
        "symbol": "NBIX",
        "title": "Neurocrine Biosciences gets FDA OK for movement disorder drug "
    },
    {
        "content": "* Neurocrine announces FDA approval of Ingrezza TM (valbenazine) capsules as the first and only approved treatment for adults with tardive dyskinesia (TD)",
        "date": "04112017",
        "name": "Neurocrine Biosciences Inc",
        "news_type": "normal",
        "symbol": "NBIX",
        "title": "BRIEF-Neurocrine announces FDA approval of Ingrezza TM (valbenazine) capsules "
    },
    {
        "content": "* Positive results from Kinect 3 phase iii study of Ingrezza (valbenazine) for treatment of tardive dyskinesia (td)",
        "date": "03212017",
        "name": "Neurocrine Biosciences Inc",
        "news_type": "topStory",
        "symbol": "NBIX",
        "title": "BRIEF-Neurocrine Biosciences reports positive results from study of Ingrezza "
    },
    {
        "content": "* Neurocrine Biosciences reports year-end 2016 results and provides investor update for 2017",
        "date": "02142017",
        "name": "Neurocrine Biosciences Inc",
        "news_type": "topStory",
        "symbol": "NBIX",
        "title": "BRIEF-Neurocrine Biosciences reports Q4 loss per share $0.51 "
    },
    {
        "content": "* Neurocrine and Bial announce exclusive North American licensing agreement for opicapone",
        "date": "02092017",
        "name": "Neurocrine Biosciences Inc",
        "news_type": "topStory",
        "symbol": "NBIX",
        "title": "BRIEF-Neurocrine and Bial reports exclusive North American licensing agreement for opicapone "
    },
    {
        "content": "* Neurocrine announces completion of phase II clinical study of VMAT2 inhibitor Ingrezza (valbenazine) in adults with tourette syndrome",
        "date": "01172017",
        "name": "Neurocrine Biosciences Inc",
        "news_type": "topStory",
        "symbol": "NBIX",
        "title": "BRIEF-Neurocrine announces completion of phase II clinical study of VMAT2 Inhibitor Ingrezza "
    },
    {
        "content": "* Neurocrine announces FDA advisory committee meeting to review Ingrezza\u007f (valbenazine) new drug application for the treatment of tardive dyskinesia",
        "date": "11292016",
        "name": "Neurocrine Biosciences Inc",
        "news_type": "topStory",
        "symbol": "NBIX",
        "title": "BRIEF-Neurocrine Biosciences announces FDA advisory committee meeting to review Ingrezza NDA "
    },
    {
        "content": "* Q3 earnings per share view $-0.57 -- Thomson Reuters I/B/E/S",
        "date": "11022016",
        "name": "Neurocrine Biosciences Inc",
        "news_type": "topStory",
        "symbol": "NBIX",
        "title": "BRIEF-Neurocrine Biosciences posts Q3 loss per share $0.43 "
    },
    {
        "content": "* Neurocrine announces FDA conditional acceptance of proprietary name Ingrezza\u007f for VMAT2 inhibitor valbenazine",
        "date": "08312016",
        "name": "Neurocrine Biosciences Inc",
        "news_type": "topStory",
        "symbol": "NBIX",
        "title": "BRIEF-Neurocrine announces FDA conditional acceptance of Ingrezza "
    },
    {
        "content": "* Submits new drug application for Valbenazine for treatment of tardive dyskinesia",
        "date": "08292016",
        "name": "Neurocrine Biosciences Inc",
        "news_type": "topStory",
        "symbol": "NBIX",
        "title": "BRIEF-Neurocrine submits NDA for Valbenazine "
    },
    {
        "content": "* Q2 earnings per share view $-0.49 -- Thomson Reuters I/B/E/S",
        "date": "08032016",
        "name": "Neurocrine Biosciences Inc",
        "news_type": "topStory",
        "symbol": "NBIX",
        "title": "BRIEF-Neurocrine Biosciences Q2 loss per share $0.46 "
    },
    {
        "content": "* Neurocrine announces initiation of a long-term phase ii clinical study of vmat2 inhibitor valbenazine in tourette syndrome  Source text for Eikon:  Further company coverage:",
        "date": "07282016",
        "name": "Neurocrine Biosciences Inc",
        "news_type": "topStory",
        "symbol": "NBIX",
        "title": "BRIEF-Neurocrine announces start of phase ii study of tourette "
    },
    {
        "content": "* Q1 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S",
        "date": "05052016",
        "name": "Neurocrine Biosciences Inc",
        "news_type": "topStory",
        "symbol": "NBIX",
        "title": "BRIEF-Neurocrine Biosciences reports Q1 loss per share $0.22 "
    },
    {
        "content": "Neurocrine Biosciences Inc's experimental drug for tardive dyskinesia  a neurological disorder  was effective in a late-stage study  bringing it a step closer to becoming the first treatment to win U.S. approval for the condition.",
        "date": "10082015",
        "name": "Neurocrine Biosciences Inc",
        "news_type": "topStory",
        "symbol": "NBIX",
        "title": "Neurocrine's neurological disorder drug effective in late: stage study "
    },
    {
        "content": "Oct 8 Neurocrine Biosciences Inc's  experimental drug for tardive dyskinesia  a neurological disorder  was effective in a late-stage study  bringing it a step closer to becoming the first treatment to win U.S. approval for the condition.",
        "date": "10082015",
        "name": "Neurocrine Biosciences Inc",
        "news_type": "normal",
        "symbol": "NBIX",
        "title": "Neurocrine's neurological disorder drug effective in late-stage study "
    },
    {
        "content": "June 8 Biotechnology company Neurocrine Biosciences Inc said it had suspended two planned clinical trials of its experimental drug to treat a potentially life-threatening genetic disorder called congenital adrenal hyperplasia.",
        "date": "06082015",
        "name": "Neurocrine Biosciences Inc",
        "news_type": "normal",
        "symbol": "NBIX",
        "title": "Neurocrine suspends two planned trials of genetic disorder drug "
    },
    {
        "content": "Jan 8 An experimental drug being developed by AbbVie Inc and Neurocrine Biosciences Inc  successfully reduced symptoms of endometriosis in premenopausal women in the first of two late-stage studies.",
        "date": "01082015",
        "name": "Neurocrine Biosciences Inc",
        "news_type": "normal",
        "symbol": "NBIX",
        "title": "AbbVie  Neurocrine drug successful in endometriosis trial "
    },
    {
        "content": "Jan 8 An experimental drug being developed by AbbVie Inc and Neurocrine Biosciences Inc  successfully reduced symptoms of endometriosis in pre-menopausal women in the first of two late-stage studies.",
        "date": "01082015",
        "name": "Neurocrine Biosciences Inc",
        "news_type": "normal",
        "symbol": "NBIX",
        "title": "UPDATE 1-AbbVie  Neurocrine drug successful in endometriosis trial "
    }
]